NASDAQ: AUTL - Autolus Therapeutics plc

Yield per half year: -46.98%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Autolus Therapeutics plc

Extended chart Simple chart
Financial Markets by TradingView

About Autolus Therapeutics plc

Autolus Therapeutics plc, биофармацевтическая компания, работающая на клинической стадии, разрабатывает Т-клеточную терапию для лечения рака. Компания разрабатывает AUTO1 и AUTO3 для лечения В-клеточных злокачественных новообразований; AUTO2 и AUTO8 для лечения множественной миеломы; AUTO1 / 22 для лечения CAR-T с двойным нацеливанием; AUTO3NG для лечения гематологического рака; AUTO4 и AUTO5 для Т-клеточной лимфомы; AUTO6NG для лечения запрограммированной терапии Т-клетками; AUTO6 для лечения нейробластомы; и AUTO7 для лечения рака простаты.

more details
Компания Autolus Therapeutics plc была основана в 2014 году, ее штаб-квартира находится в Лондоне, Великобритания.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2018-06-22
ISIN US05280R1005
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://www.autolus.com
Цена ао 2.28
Change price per day: +3.49% (2.29)
Change price per week: +6.76% (2.22)
Change price per month: +5.33% (2.25)
Change price per 3 month: -46.62% (4.44)
Change price per half year: -46.98% (4.47)
Change price per year: -60.1% (5.94)
Change price per 3 year: -50.52% (4.79)
Change price per 5 year: -74.49% (9.29)
Change price per 10 year: 0% (2.37)
Change price per year to date: +8.72% (2.18)
All parameters

Underestimation

Title Value Grade
P/S 669.95 1
P/BV 10.2 1
P/E 0 0
EV/EBITDA -5.05 0
Total: 2.75

Efficiency

Title Value Grade
ROA, % -55.51 0
ROE, % -186.93 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.281 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % -43.4 0
Yield Ebitda, % 16.65 3
Yield EPS, % -58.4 0
Total: 3.2
More

Institutions Volume Share, %
Syncona Portfolio Ltd 21346829 8.03
Blackstone Inc 20485611 7.7
Paradigm Biocapital Advisors LP 12611335 4.74
Deep Track Capital, LP 11869297 4.46
TFG Asset Management GP Ltd 8000000 3.01
Cormorant Asset Management, LP 5450000 2.05
Armistice Capital, LLC 3850000 1.45
Adage Capital Partners GP L.L.C. 3825532 1.44
Frazier Life Sciences Management, L.P. 3746857 1.41
Price (T.Rowe) Associates Inc 3001208 1.13

ETF Share, % Profitability for 1 year, % Dividends, %
Range Cancer Therapeutics ETF 0.92787 47.24 0.11955
Virtus LifeSci Biotech Clinical Trials ETF 0.65217 63.04 0.33
SPDR S&P Kensho New Economies Composite ETF 0.103 21.57 0.88486
Invesco Nasdaq Biotechnology ETF 0.07395 28.58 0.8565
Future Tech ETF 0.07215 426.34 0.8416
Principal Healthcare Innovators ETF 0.07215 618.5 0.8416
ProShares Ultra Nasdaq Biotechnology 0.0513 51.7 0.85651
SPDR S&P International Small Cap ETF 0.04123 8.94 3.10348



Head Job title Payment Year of birth
Mr. Christopher Vann Senior VP & COO N/A 1965 (60 years)
Mr. David Brochu Senior VP & Chief Technical Officer N/A 1956 (69 years)
Mr. Brent Rice Senior VP, Chief Commercial Officer & Site Head of US N/A 1966 (59 years)
Dr. Christian Martin Itin Ph.D. CEO & Director 2.43M 1964 (61 year)
Dr. Martin Pule M.D., MBBS Founder, Senior VP & Chief Scientific Officer N/A 1972 (53 years)
Mr. Robert F. Dolski Senior VP & CFO 1971 (54 years)
Mr. Alexander Swan Senior VP & Chief Human Resources Officer 1965 (60 years)
Ms. Olivia Manser Director of Investor Relations
Mr. Alex Driggs Senior VP of Legal Affairs & General Counsel and Secretary
Dr. Chris Williams Senior VP & Chief Business Development Officer 1980 (45 years)

Address: United Kingdom, London W RZ, Forest House - open in Google maps, open in Yandex maps
Website: http://www.autolus.com